

# Zambia

| High HIV burden |

## Tuberculosis profile

Population 2013

15 million

Estimates of TB burden * 2013	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	3.6 (2.3–4.7)	25 (16–33)
Mortality (HIV+TB only)	8.6 (6.8–11)	59 (47–73)
Prevalence (includes HIV+TB)	49 (28–76)	338 (193–524)
Incidence (includes HIV+TB)	60 (56–64)	410 (387–440)
Incidence (HIV+TB only)	37 (35–40)	255 (240–274)
Case detection, all forms (%)	68 (64–72)	

Estimates of MDR-TB burden * 2013	New	Retreatment
% of TB cases with MDR-TB	0.3 (0–1.2)	8.1 (4.1–14)
MDR-TB cases among notified pulmonary TB cases	88 (0–350)	570 (290–980)

TB case notifications 2013	New **	Relapse
Pulmonary, bacteriologically confirmed	12 238	1 863
Pulmonary, clinically diagnosed	17 167	
Extrapulmonary	9 370	

<b>Total new and relapse</b>	<b>40 638</b>
Previously treated, excluding relapses	5 155
<b>Total cases notified</b>	<b>45 793</b>

Among 40 638 new and relapse cases:

3 154 (8%) cases aged under 15 years; male:female ratio: 1.5

Reported cases of RR-/MDR-TB 2013	New	Retreatment	Total **
Cases tested for RR-/MDR-TB			
Laboratory-confirmed RR-/MDR-TB cases			79
Patients started on MDR-TB treatment			79

TB/HIV 2013	Number	(%)
TB patients with known HIV status	41 305	(90)
HIV-positive TB patients	25 476	(62)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)	23 769	(93)
HIV-positive TB patients on antiretroviral therapy (ART)	16 945	(67)
HIV-positive people screened for TB		
HIV-positive people provided with IPT		

Treatment success rate	(%)
New and relapse cases registered in 2012	85
Previously treated cases, excluding relapse, registered in 2012	79
HIV-positive TB cases, all types, registered in 2012	
RR-/MDR-TB cases started on second-line treatment in 2011	29
XDR-TB cases started on second-line treatment in 2011	


Laboratories 2013	
Smear (per 100 000 population)	2.5
Culture (per 5 million population)	1.0
Drug susceptibility testing (per 5 million population)	
Sites performing Xpert MTB/RIF	
Is second-line drug susceptibility testing available?	Yes, in country

Financing TB control 2014	
National TB programme budget (US\$ millions)	16
% Funded domestically	44%
% Funded internationally	56%
% Unfunded	0%

\* Ranges represent uncertainty intervals


\*\* Includes cases with unknown previous TB treatment history

(Rate per 100 000 population per year)




Mortality (excludes HIV+TB)

(Rate per 100 000 population)




Prevalence

(Rate per 100 000 population per year)




Notified (new and relapse) Incidence  
Incidence (HIV+TB only)

(Number of patients)




HIV-positive TB patients  
on CPT on ART

Treatment success rate (%)



New Retreatment  
New and relapse Retreatment, excluding relapse  
HIV-positive RR-/MDR-TB XDR-TB

Total budget (US\$ millions)



Funded domestically Funded internationally  
Unfunded